Molecular Diagnostics and Imaging Technologies Role In Drug Development to Be Featured at Industry Conference in Princeton, NJ

Nov 09, 2004, 00:00 ET from Strategic Research Institute

    NEW YORK, Nov. 9 /PRNewswire/ -- Research advances in molecular
 diagnostics, imaging, and nanotechnology, and their impact on drug development
 will be presented by a faculty of 20+ leading researchers at an industry forum
 geared towards networking and discussion, announces Strategic Research
     Genomic, proteomic, and metabolite markers, pharmacogenomic applications,
 in vivo imaging, and nanotechnology will be addressed, along with their
 translation into current efforts in optimizing diagnosis and therapeutic
     Presenters include: Pfizer, Eli Lilly, Bristol Myers Squibb, Bayer
 Diagnostics, Celera Diagnostics, Quest Diagnostics, Epix Pharmaceuticals,
 National Cancer Institute, National Center for Genome Resources, Philips
 Medical Systems, Kereos, Cepheid, Metabolon, Abbott Laboratories, and many
     The meeting, scheduled for February, 2005, is designed to provide an open
 forum for discussion and audience participation via interactive roundtable
 discussions and workshops on commercialization, regulation, and imaging
     Agenda, registration, and detailed information is available at
     To request announcement, group discount information, or for speaking
 opportunities, please contact Steve J. Kuperberg at
 or call 212 967-0095 x261.

SOURCE Strategic Research Institute